Literature DB >> 6805121

[Local chemotherapy of bladder carcinoma with mitomycin (author's transl)].

S H Flüchter, R Harzmann, H Hlobil, W Erdmann, K H Bichler.   

Abstract

40 patients with transitional cell carcinoma of the bladder, stage Tis, Ta und Tl, were treated by a topical cytostatica-therapy with Mitomycin C (MMC) after transurethral resection of the bladder in order to investigate: 1. The curative influence on the carcinoma in situ, 2. the prevention of tumor cell implantations. After an average observation time of up to the 23.4 months this concept of therapy seems to be promising because of clearly reduced recurrence rate and the lack of systemic toxicity. MMC absorption studies with 19 patients, partly with reflux and TUR-caused perforation of the bladder, showed that MMC instillation therapy (20 mg MMC in 40 ml NaCl) immediately after resection does not result inn systemically toxic serum concentration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6805121

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  2 in total

Review 1.  Therapy of bladder cancer.

Authors:  K H Bichler; S Halim
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

2.  Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.

Authors:  R Minervini; R Felipetto; L Viganò; M Cecchi
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.